medical history don 2015 dec15 mychart healthsummry.xlsx

7/23/2019 Medical History Don 2015 Dec15 MyChart HealthSummry.xlsx

http://slidepdf.com/reader/full/medical-history-don-2015-dec15-mychart-healthsummryxlsx 1/24

Patient Health Summary -

Donald T Smith (Male, born Oct. 02, 19!" Column1

#ddre$$ %ontact &n'ormation n)li$h *an)ua)e +hite&ri$h Thoma$ Ho)an r, MD, &M, Saannah, /#

Donald T Smith

3823 West Brandon Wa Temporar Previous 2 WILDGOOSE LN 31411-2860

C/O Michele Millar Temporary

Doylestown !" 18#$2 Tempor Previous SAVANNAH, GA 31411-2860

912-398-391 !"e##$

#12%2&'%1(13 )cell%Spouse*

Column1

ote 'rom Memorial Health nier$ity Phy$ician$ /rou3 Dr Thoma$ Ho)an, MD, &M, Sannah, /#

%&is 'o"u(e)* "o)*+i)s i)or(+*io) *&+* +s s&+re' i*& Do)+#' % S(i*&. I* (+/ )o* "o)*+i) *&e e)*ire re"or' ro( e(ori+# He+#*& )iversi*/ P&/si"i+)s.

#ller)ie$ No )o) A##eries o) i#e

%urrent Medication$

Medication4$

%+e 1 *+5#e* !0. ( *o*+#$ 5/ (ou*& 7ID 0222014

%+e 1 *+5#e* !0. ( *o*+#$ 5/ (ou*& '+i#/ 0132014

%+e 1 *+5#e* !1 ( *o*+#$ 5/ (ou*& 2 !*o$ *i(es '+i#/. 1202013

%+e 1 "+su#e !60 ( *o*+#$ 5/ (ou*& '+i#/. 1202013

%+e 1 "+su#e 5/ (ou*& '+i#/ or ros*+*e 1202013

E: u#*i&+se 24 &r

1202013

%+e 1 *+5#e* 5/ (ou*& '+i#/. 03102014

%+e 1 *+5#e* !40 ( *o*+#$ 5/ (ou*& '+i#/ r) +)#e se##i) 1202013

(e*&o*re;+*e 2. G *+5#e* %+e si;!6$ 2. ( *+5#e*s 5/ (ou*& o)"e + ee. 0622013

%+e 22 ( 5/ (ou*& 2 !*o$ *i(es '+i#/.

%+e 1 *+5#e* !8 ( *o*+#$ 5/ (ou*& *i"e '+i#/. 1202013

*+'+#+i# !<IALIS$ 20 G *+5#e* %+e 20 ( 5/ (ou*& P or ED 1202013

%+e 1 *+5#e* !10 ( *o*+#$ 5/ (ou*& )i&*#/ or s#ee. 03212014

smith823'+,ellsouth-net

&n$truction$ Start Date

ALP:A=o#+( !>ANA>$ 0.

+*orv+s*+*i) !LIPI%O:$ 40 G

5usPI:o)e !7SPA:$ 1 G

DLo;e*i)e !<?7AL%A$ 60

'u*+s*eri'e-*+(su#osi)

eso(er+o#e !NE>I$ 40 %+e 1 "+su#e !40 ( *o*+#$ 5/ (ou*& ever/ (or)i) 5eore

o#i" +"i' !BOLVI%E$ 1 G

urose(i'e !LASI>$ 40 G

re+5+#i) !L?:I<A$ 22 G

rOPINI:o#e !:ECIP >L$ 8

o#i'e( !A7IEN$ 10 (

mailto:[email protected]

mailto:[email protected]



2015 Don Medical July SymptomsDiagnosis or Symptom Physician Etiology

Se.ere earin0 oss Dr- ena0s MD euro er.e Dama0e

!eripheral europathy Dr- ena0s MD euro 4nterrupted Bld 5low ands 6 7eet

4schemia "cute 6 ocal in 7in0ers "rms e0s "n9les and Toes :M; 6 CS

europathy demylination :M; 6 CS

er.e Dama0e 6 eoropathy )destruction* as lead to am,lyopia catracts ,lurred .ision hearin0 loss speech impairment

Carpal Tunnel Syndrom Dr- ena0s MD euro %Median ner.e ,ein0 s<uee=ed at wrist ,y enlar0ed tendons/li0aments

Carpal Tunnel Evaluate for Treat Dr. Gregory G GallantSpondylolisthesis Dr- e0arity MD Orth per5ormed Steroid 4n>ections plus O,,lation Sur0ery Ortho !ain Mna0ement

Spondylolisthesis Dr- McCormic9 MD Orth Scheduled Sur0 postponed 5or mo.e

Spondylolisth Evaluate for Treat Dr. Gregory G Gallant OrthoSurg

Shortness o5 Breath )SOB* % caused ,y clim,in0 st Dr- ena0s MD Neurology

Shortness o5 Breath )SOB* % caused ,y clim,in0 st Dr- o0an Neuro

?estless e0 S9in Syndrome )?S* Dr- o0an IM

?estless e0 S9in Syndrome )?S* Dr- Win Rhu

Sleep Depri.ation Dr- o0an IM

Sleep"pnia O,structi.e Dr- @emp Resp C%!ap to Dental"pplin

Sleep "pnia Oral Dental "ppliance Dr- Schna,el Resp DentalSur0

Osteo"rthritis Dr- Win Rhu

?heumatoid "rthritis Dr- Win Rhu

7i,romyal0ia Dr o0an IM

7i,romyal0ia Dr- Win Rhu

Orthostatic ypotension Dr o0an IM

yperlipidemia Dr o0an IM

!eripheral ascular Disease )!D* Dr o0an IM

!eripheral ascular Disease )!D* Dr- ana0s Neuro

!eripheral europathy Dr o0an IM!anic attac9 Dr o0an IM

"nAiety Dr o0an IM

Depression Dr o0an IM

Shin0les Dr- o0an IM

Multple Melanoma ),ac9 shoulders lum,ar* Dr- !rit=9er Dermatology

LEGS & FEET - Tired !estless S"elling Legs and Feet

T#ES - Chronic Frost$ite-li%e feeling

ypoglyce'ia - #ccasional episodes causing lightheadness nausea & ( upset

Generali)ed - !estriction in $lood supply % causin0 a shorta0e o5 oAy0en 5or cellular meta,olism )to 9eep tissue ali.e*



PVD Peri&er+# V+s"u#+r Dise+se

<&ro)i" I)#+((+*or/ Peri&er+# Neuro+*&/

Peri&er+# De(/#i)+*io)

DDD Dee)er+*ive Dise+se

Her)i+*e' Dis" Dise+se

S"i+*i" Nerve Issues

<+r+# %u))e# S/)'ro(e

Is"&e(i+

<&ro)i" I)#+((+*or/ Po#/Neuro+*&/

SO7 S&or*)ess o 7re+*&

Ni&* Se+*s

A(5#/oi+

7#urre' Visio)

Dr/ E/es

Severe He+ri) Loss

Deor(e' P+i)u# %oes <ur#i) )'er Si'e+/s

7e)i) Le B+"i"u#+*io)s

A);ie*/ ro5#e( !A);ie*/ s*+*e, u)se"iie'$

<+ro*i' +r*er/ )+rroi) !<+ro*i' s*e)osis$ 01232014

Dii"u#*/ +##i) or s*+/i) +s#ee !I)so()i+$ 01092014

E)#+re' ros*+*e !H/er*ro&/ o ros*+*e i*&ou* uri)+r/ o5s*ru"*io) +)' o*&er #oer uri)+r/ *r+"* s/(*o(s !L%S$

Hi& 5#oo' ressure !Esse)*i+# &/er*e)sio), 5e)i)$

Hi& "&o#es*ero# !H/er"&o#es*ero#e(i+$

oo' ro5#e( !+or 'eressive 'isor'er, re"urre)* eiso'e, (o'er+*e$

:es*#ess #es s/)'ro(e !:LS !res*#ess #es s/)'ro(e$$ 0162013

:&eu(+*oi' +r*&ri*is

:ou*i)e (e'i"+# e;+( !:ou*i)e e)er+# (e'i"+# e;+(i)+*io) +* + &e+#*& "+re +"i#i*/$

S#ee +)e+ !S#ee +)e+, o5s*ru"*ive$ 01092014

&mmuni5ation$

I)#ue)+ !Hi& Dose$ 10012013

I)#ue)+ LAIV !N+s+#$ 10102012

P)eu(o"o""+# <o)u+*e -V+#e)* 10102012

%'+ 01102013

P d

Problem

ame Date$ /ien



Le* S&ou#'er !Sir+# Ne" Br+"*ure$ 101982 7<H, *Ho#/, N@

S&+r-7i*e Sur o) %ru), 5o* SF #)(+ 1989 - 2009 1989 *o 2009 N@

E+r Lo5e !:i&*$ :e(ove' 1990 N@

e5t ?in0 7in0er !4! ?econstruction 1##2

Si)+# Lu(5+r He(+)io(+ 2008 GA

Cer.ical 7iAation C(%C 2$$# GA

a.al ernia 2$1$ GA

e5t Shoulder Torn Tendons 6 i0aments ?epair2$1& GA

?i0ht Shoulder Torn Tendons6 i0aments ?epair2$1& GA

Saddle Bloc9s epidorals 5acets 3 & ( S1 2$$# to 2$1& GACarpol Tunnel Bi%ateral 2$1( TO B: :""T:D 6 T?:"T:D

Spondolythesis S1 2$1( TO B: :""T:D 6 T?:"T:D

1!201! 1!201!%OMP6HS&7 MT#O*&% P#* - :inal re$ult (1!201! ;30 6an)e



So'iu( 142 13-144 ((o#L

Po*+ssiu( 4.3 3.6-.1 ((o#L

<&#ori'e 108 101-111 ((o#L

<O2 30 22-32 ((o#L

22 HIGH 9-20 ('#

<re+*i)i)e, Ser 1 0.9-1.3 ('#

A)io) G+ 8 -16 ((o#L

Protein total < LOW 6.1-.9 '#

A#5u(i) 3.8 3.-.0 '#

G#o5u#i), %o*+# 2.2 2.4-4.2 '#

AG :+*io 1. 1.1-2.2

<+#"iu( 8.9 8.4-10.3 ('#

A#+#i)e &os 8 2-120 L

AS% 2 1-9 L

AL% 19 1-63 L

7i#iru5i) %o*+# 0.8 0.4-2.0 ('#

GB: D:D A A(er 60 9 :A%E

GB: D:D No) A A(er 60 9 :A%E

1!201! 1!201!

Tri)lyceride$ 9= 3-13 ('#>>> 0-200 ('# H&/H

<&o#HDL :+*i 4.2 0.0-4.2

HDL

0-100 ('# H&/H19 ('#

11102011 111011

%% +D&::6T&#* (%% #D D&::6T&#*" - :inal re$ult (11102011 132= PM ST"

W7< 6.9 4.3-11.0 <

6% !.9; *O+ .=1-=.9! M&*% M

He(o#o5i) 13.4 13.3-18.6 'L

Hematocrit !?. *O+ !9.=-==.? @

<V 9 -102 < I<:

<H 33.8 2.0-32.0 PI<O G.

<H< 3 32.0-36. '#

6D+ 1.< H&/H 11.=-1.= @

P#+*e#e* <ou)* 2 10-42 <

PV .8 .2-10.6 < I<:

Neu*ro&i#s :e#+*ive .2 40.0-80.0

L/(&o"/*es :e#+*ive 29.6 10.0-4.0

o)o"/*es :e#+*ive 8.3 2.0-11.0

Eosi)o&i#s :e#+*ive 4.4 0.-.8

7+so&i#s :e#+*ive 0. 0.2-1.1

Neu*ro&i#s A5so#u*e 4 1.9-.2 %HuL

L & * A5 # * 2 1 1 2 %H L

P#*" - :inal re$ult (010!201! ;30 #M ST"

6an)e

<&o#es*ero#,

8

('#

VLDL <&o#es*ero#



Eosi)o&i#s A5so#u*e 0.3 0.0-0. %HuL

7+so&i#s A5so#u*e 0 0.0-0.1 %HuL

11102011

%OMP6HS&7 MT#O*&% P#* - :inal re$ult (11102011 132= PM ST"

G#u"ose 92 -110 ('#

So'iu( 142 3-144 ((o#L

Po*+ssiu( 4.3 3.6-.1 ((o#L

<&#ori'e 102 101-111 ((o#L

<O2 30 22-32 ((o#L

7N 14 9-20 ('#

%reatinine, Ser 0.? *O+ 0.9-1.! m)dl

A)io) G+ 14 -16 ((o#L

Protein total =.9 *O+ <.1-;.9 )dl

A#5u(i) 3.9 3.-.0 '#

G#o5u#i), %o*+# 2 2.4-4.2 '#

AG :+*io 2 1.1-2.2

<+#"iu( 9.1 8.4-10.3 ('#

A#+#i)e &os 90 2-120 L

AS% 33 1-9 L

AL% 23 1-63 L

7i#iru5i) %o*+# 0.9 0.4-2.0 ('#

GB: D:D A A(er 60 9- :A%E

GB: D:D No) A A(er 60 9- :A%E

11102011 111011

%ri#/"eri'es 103 3-13 ('#

%hole$terol, Total 21< H&/H 0-200 m)dl

%holHD* 6atio . H&/H 0.0-.2

*D* %hole$terol 1; H&/H 0-100 m)dl

VLDL <&o#es*ero# <+# 21 ('#

?1<2011 ?1<2011

%% +D&::6T&#* (%% #D D&::6T&#*" - :inal re$ult (0?1<2011"

W7< 8. 4.3-11.0 <

6% .2? *O+ .=1-=.9! M&*% M

He(o#o5i) 13.9 13.3-18.6 'L

He(+*o"ri* 40.4 39.-.8

<V 9 -102 < I<:

<H 32.4 2.0-32.0 PI<O G.

<H< 34.3 32.0-36. '#

:DW 12 8 11 14

*&P&D P#* +%HO*ST6O*HD* 6#T&O (*&P&D P#*" - :inal re$ult (11102011 132= PM ST"

HDL 49 ('#

PV 8 2 10 6 < I<:



PV .8 .2-10.6 < I<:

Neu*ro&i#s :e#+*ive 66.1 40.0-80.0

L/(&o"/*es :e#+*ive 22.9 10.0-4.0

o)o"/*es :e#+*ive 2.0-11.0

Eosi)o&i#s :e#+*ive 3. 0.-.8

7+so&i#s :e#+*ive 0. 0.2-1.1

Neu*ro&i#s A5so#u*e .8 1.9-.2 %HuL

L/(&o"/*es A5so#u*e 2 1.1-2. %HuL

o)o"/*es A5so#u*e 0.6 0.3-0.8 %HuL

Eosi)o&i#s A5so#u*e 0.3 .0-0. %HuL

7+so&i#s A5so#u*e 0 0.0-0.1 %HuL

?1<2011

G#u"ose 99 -110 ('#

So'iu( 141 13-144 ((o#L

Po*+ssiu( 4.6 3.6-.1 ((o#L

%hloride 101 *O+ 101-111 mmol*

%O2 != H&/H 22-!2 mmol*

7N 1 9-20 ('#

%reatinine, Ser 0.9 *O+ 0.9-1.! m)dl

A)io) G+ 10 -16 ((o#L

Pro*ei) *o*+# 6. 6.1-.9 '#

A#5u(i) 4.1 3.-.0 '#

/lobulin, Total 2. *O+ 2.-.2 )dl

AG :+*io 1. 1.1-2.2

<+#"iu( 9.3 8.4-10.3 ('#

#l8aline ho$ 12; H&/H 2=-120 *

AS% 2 1-9 L

AL% 26 1-63 L

7i#iru5i) %o*+# 0.9 0.4-2.0 ('#



?1<2011 ?1<2011

Tri)lyceride$ 1== H&/H !=-1!= m)dl

%hole$terol, Total 2!= H&/H 0-200 m)dl

%holHD* 6atio .! H&/H 0.0-.2

*D* %hole$terol 1=0 H&/H 0-100 m)dl

VLDL <&o#es*ero# <+# 31 ('#

<2?2011 <2?2011

%OMP6HS&7 MT#O*&% P#* - :inal re$ult (0?1<2011 131= PM DT" 7alue

-

HDL 4 ('#

%% +D&::6T&#* (%% #D D&::6T&#*" :i l lt (0<2?2011 = 20 PM DT" 7 l

:7< 4 1



:7< 4.1

He(o#o5i) 14

He(+*o"ri* 40

<V 96

<H 33.

<H< 34.9

:DW 14.4

P#+*e#e* <ou)* 269

PV .2

Neu*ro&i#s :e#+*ive 68

L/(&o"/*es :e#+*ive 21.9

o)o"/*es :e#+*ive 4.6

Eosi)o&i#s :e#+*ive 4.

7+so&i#s :e#+*ive 0.8

Neu*ro&i#s A5so#u*e

L/(&o"/*es A5so#u*e 1.6

o)o"/*es A5so#u*e 0.3

Eosi)o&i#s A5so#u*e 0.3

7+so&i#s A5so#u*e 0.1

<2?2011

G#u"ose 9 -110 ('#

So'iu( 141 13-144 ((o#L

Po*+ssiu( 4.4 3 .6-.1 ((o#L

<&#ori'e 104 101-111 ((o#L

<O2 32 22-32 ((o#L

7N 12 9-20 ('#

<re+*i)i)e, Ser 0.8 0.9-1.3 ('#

A)io) G+ 9 -16 ((o#L

Pro*ei) *o*+# 6.3 6.1-.9 '#

A#5u(i) 4.1 3.-.0 '#

G#o5u#i), %o*+# 2.2 2.4-4.2 '#

AG :+*io 1.9 1.1-2.2

<+#"iu( 9.1 8.4-10.3 ('#

A#+#i)e &os 101 2-120 L

AS% 38 1-9 L

AL% 3 1-63 L

7i#iru5i) %o*+# 1 0.4-2.0 ('#

<&o#es*ero#, %o*+# 13 0-200 ('#



<2?2011

% * # < 4 49 0 14 0

-

-6an)e

I 0 4 182 '#



Iro) 0 4-182 u'#

%r+)serri) 242 180-329 ('#

%I7< 339 2-40 u'#

Iro) S+*ur+*io) 21 20-0

<2?2011

Berri*i) 211 24-336 )(#

Bo#+*e, He(o#/s+*e 809 23-1400 )(#

Vi*+(i) 7-12 3 180.0-914.0

:e*i" <* P"* 1.3 0.-3.0

<2?2011 <2?2011

Pro*ei) *o*+# 6.3 6.1-.9 '#

A#5u(i) 3.9 3.-.0 '#

7i#iru5i) %o*+# 0. 0.4-2.0 ('#

G+((+ G#o5u#i) 18 -64 L

LD 181 98-192 L

AS% 30 1-9 L

AL% 31 1-63 L

A#+#i)e &os 11 2-120 L

=2011 =2011

W7< .2 4.3-11.0 <

:7< 4.29 4.1-.93 IL<

He(o#o5i) 14 13.3-18.6 'L

He(+*o"ri* 40.3 39.-.8

<V 94 -102 < I<:

<H 32. 2.0-32.0 PI<O G.

<H< 34.9 32.0-36. '#

:DW 14 11.-14.

P#+*e#e* <ou)* 239 10-42 <

PV .8 .2-10.6 < I<:

Neu*ro&i#s :e#+*ive .6 40.0-80.0

L/(&o"/*es :e#+*ive 29.4 10.0-4.0

o)o"/*es :e#+*ive 9.1 2.0-11.0

Eosi)o&i#s :e#+*ive . 0.-.8

7+so&i#s :e#+*ive 0.2 0.2-1.1

Neu*ro&i#s A5so#u*e 2.9 1.9-.2 %HuLL/(&o"/*es A5so#u*e 1. 1.1-2. %HuL

o)o"/*es A5so#u*e 0. 0.3-0.8 %HuL


7 &i# A5 # * 0 0 0 0 1 %H L

-6an)e

-6an)e

-6an)e

-6an)e

-6an)e

-6an)e

6an)e



G#u"ose 106 -110 ('#

So'iu( 139 13-144 ((o#L

Po*+ssiu( 4.6 3.6-.1 ((o#L

<&#ori'e 102 101-111 ((o#L

<O2 31 22-32 ((o#L

7N 19 9-20 ('#

<re+*i)i)e, Ser 0.9 0.9-1.3 ('#

A)io) G+ 11 -16 ((o#L

Pro*ei) *o*+# 6.6 6.1-.9 '#

A#5u(i) 4.2 3.-.0 '#

G#o5u#i), %o*+# 2.4 2.4-4.2 '#

AG :+*io 1. 1.1-2.2

<+#"iu( 9.4 8.4-10.3 ('#

A#+#i)e &os 9 2-120 L

AS% 28 1-9 L

AL% 24 1-63 L

7i#iru5i) %o*+# 0.9 0.4-2.0 ('#


GB: D:D No) A A 60 9- :A%E

=2011 =2011

%ri#/"eri'es 80 3-13 ('#

%hole$terol, Total 2!< H&/ 0-200 ('#

<&o#HDL :+*io 3.3 0.0-4.2

*D* %hole$terol 19 H&/H 0-100 m)dl

VLDL <&o#es*ero# <+# 16 ('#

=2011

PSA 1.44 0.00-4.00 )(L

1<2011 1<2011

Se' :+*e 0-20 ((&r.

1<2011

SO ANA !His*ori"+#$ SEN% %O < LA7

1<2011

1<2011

- 6an)e

-6an)e

HDL 1 ('# <o((e)*t3 LOW RISK IS GREATER THAN OR EQUAL TO 60 MG/DL HIGH RISK IS LESS THAN 40 MG/DL

-

, , -

-

6HM#TO&D :#%TO6 (H&STO6&%#*" - :inal re$ult (010<2011 123! PM ST"

%es*os*ero)e 4 4 2 4 9 )'#



%es*os*ero)e 4.4 2.4-9. )'#

SO L?E !His*ori"+#$ SEN% %O :EBE:EN<E LA7

1<2011 1<2011

SO HP#T&T&S % # - :inal re$ult (010<2011 123! PM ST"

SO HEPA%I%IS < A7 !His*ori"+#$ SEN% %O < LA7

> 12;2010 12;2010 12;2010 12/7/2010

%% +D&::6T&#* (%% #D D&::6T&#*" - :inal re$ult (12

W7< .8 4.3-11.0 <

6% .09 *O+ 4.1-.93 IL<

He(o#o5i) 13.1 13.3-18.6 'L

Hematocrit !;.1 *O+ 39.-.8

<V 91 -102 < I<:

<H 32.2 2.0-32.0 PI<O G.

<H< 3. 32.0-36. '#

:DW 12.6 11.-14.

P#+*e#e* <ou)* 163 10-42 <

PV 8.4 .2-10.6 < I<:

Neu*ro&i#s :e#+*ive 64. 40.0-80.0

L/(&o"/*es :e#+*ive 23.8 10.0-4.0

o)o"/*es :e#+*ive .2 2.0-11.0

Eosi)o&i#s :e#+*ive 3. 0.-.8

7+so&i#s :e#+*ive 0.6 0.2-1.1

Neu*ro&i#s A5so#u*e 3.8 1.9-.2 %HuL

L/(&o"/*es A5so#u*e 1.4 1.1-2. %HuL

o)o"/*es A5so#u*e 0.4 0.3-0.8 %HuL


7+so&i#s A5so#u*e 0 0.0-0.1 %HuL

Se' :+*e 0-20 ((&r.

> 12;2010 12;2010 12;2010

G#u"ose 14 -110 ('#

So'iu( 139 13-144 ((o#LPo*+ssiu( 4.8 3.6-.1 ((o#L

<&#ori'e 103 101-111 ((o#L

<O2 31 22-32 ((o#L

7N 16 9 20 '#

SO *CM - :inal re$ult (010<2011 123! PM ST" %omonent 6an)e

6an)e

6an)e

, , -

-6an)e

A)io) G+ 10 16 ((o#L



A)io) G+ 10 -16 ((o#L

Pro*ei) *o*+# .9 6.1-.9 '#

A#5u(i) !.9 3.-.0 '#

/lobulin, Total 2 *O+ 2.4-4.2 '#

AG :+*io 2 1.1-2.2

<+#"iu( 9 8.4-10.3 ('#

#l8aline ho$ 129 H&/H 2-120 L

AS% 36 1-9 L

AL% 28 1-63 L

7i#iru5i) %o*+# 0.6 0.4-2.0 ('#

<&o#es*ero#, %o*+# 130 0-200 ('#



> 12;2010 12;2010 12;2010

%SH 0.6 0.34-.0 uI(L

4019 0.64 0.80-1.640 )'#

%omonent 7alue

SO ANA !His*ori"+#$ SEN% %O < LA7

> 12;2010 12;2010 12;2010 12;2010

6HM#TO&D :#%TO6 (H&STO6&%#*" - :inal re$ult (120;2010 1232 PM ST"

HM %O*OOS%OPC - :inal re$ult (09092010 12300 #M DT"

%omonent

HM %olono$coy "o(#e*e 12/07/10 12/7/2010

TSH - :inal re$ult (120;2010

%omonent 7alue 6an)e

T, :6 (D&6%T" (T, :6" - :inal re$ult (120;2010 1232 PM ST"

%omonent 7alue 6an)e

## - :inal re$ult (120;2010 1232 PM ST"

7alue 6an)e

medical history don 2015 dec15 mychart healthsummry.xlsx

Documents